查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2030056

全球醫藥和生物製藥契約製造市場－產業規模、佔有率、趨勢、機會和預測：按產品類型、服務、地區和競爭格局分類，2021-2031年

Pharmaceutical & Biopharmaceutical Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Service, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球藥品和生物製藥契約製造市場預計將從 2025 年的 142.3 億美元成長到 2031 年的 204.3 億美元，複合年成長率為 6.21%。

這個領域的核心在於將藥物研發的各個階段，包括研發、生產和包裝，外包給專業的外部公司。透過利用這些外部資源、基礎設施和技術進步，製藥公司可以專注於自身優勢，尤其是研發。這一成長主要受藥物研發管線日益複雜化（特別是生技藥品和前沿治療方法）以及對成本效益高的資源配置和專業生產技能的需求所驅動。為了凸顯外包生產的必要性，製藥、化學及相關技術協會 (DCAT) 在 2025 年 3 月發布的報告顯示，超過 23,000 個分子正在積極推進臨床前和 III 期臨床試驗階段。

市場概覽
預測期 2027-2031
市場規模：2025年 142.3億美元
市場規模：2031年 204.3億美元
複合年成長率：2026-2031年 6.21%
成長最快的細分市場 活性藥物成分（API）
最大的市場 北美洲

另一方面，醫藥製造業長期面臨勞動力和專業技能短缺的困境，這可能是阻礙市場發展的一大挑戰。缺乏訓練有素的員工限制了契約製造製造商的生產能力，使其難以滿足日益成長的客戶需求並推動創新。因此，該行業必須在應對這些營運難題的同時，滿足嚴格的監管要求並維持高標準的品質。

市場促進因素

全球醫藥和生物製藥契約製造行業的主要驅動力是對先進治療方法和生物製藥日益成長的需求。抗體藥物複合體(ADC) 和雙特異性抗體等複雜治療方法需要獨特的生產方法、先進的設備和專業知識，而這些往往是製藥和生物技術公司所缺乏的。透過利用合約開發和生產組織 (CDMO)，創新者無需在專業人員和設施方面進行大量投資即可獲得這些關鍵服務。例如，藥明生物在 2026 年 3 月的年度報告中揭露，該公司在 2025 年新增了創紀錄的 209 個整合項目。其中三分之二的專案專注於 ADC 和雙特異性抗體等複雜生物製藥，這凸顯了企業對 CDMO 在先進療法生產方面日益成長的依賴性。

此外，持續轉向外包模式是市場成長的主要驅動力。企業有意與合約研發生產機構（CDMO）合作，以降低資本成本、提高財務效率並縮短研發週期，從而能夠優先投入研發。尤其是中小型生物製藥公司，正從這些外部合作夥伴提供的監管專業知識和現成的生產基礎設施中獲益匪淺。截至2025年底，藥明生物表示，其合約研發生產機構（CRDMO）平台正在支援945個正在進行的一體化生物製藥項目，這表明整個產業正大力轉向策略性外包生產。同時，對大規模生產能力的投資正在增強市場的穩定性。例如，賽默飛世爾科技於2025年4月宣布計畫在未來四年內向其美國業務投資20億美元，其中15億美元將用於擴大生產能力。

市場挑戰

全球醫藥和生物製藥契約製造產業發展面臨的主要障礙之一是勞動力和專業技能的長期短缺。缺乏訓練有素的專業人員直接限制了契約製造的生產能力，阻礙了其業務擴張，也使其難以滿足客戶日益成長的藥物研發和生產服務需求。

合格人才短缺導致營運停滯，並直接阻礙市場成長。根據美國全國製造商協會 (NAM) 統計，2025 年第三季美國製造商的平均職缺率僅為 4.2% 左右，其中 25% 的製造商面臨超過 5% 的職缺。這種持續的人才短缺將減緩新業務的快速推出和現有合約的順利履行，尤其是在需要生產先進治療方法和複雜生物製藥的細分領域，最終限制契約製造的財務成長。

市場趨勢

全球製藥和生物製藥契約製造行業正經歷一場重大變革，而人工智慧 (AI) 和數位化技術的普及應用是推動這項變革的主要動力。合約研發生產機構 (CDMO) 正穩步部署基於人工智慧的工具和先進的分析方法，以最佳化生產流程、提升品質保證並增強整體營運績效。透過採用這些技術，企業能夠預測營運延誤，並在從初步研發到最終商業化的整個藥物生命週期中降低生產風險。例如，Lonza 公司在 2025 年初在其主要生物製藥業務中實施了人工智慧主導的製程分析技術 (PAT)，成功地將預測的批次缺陷率降低了 15%。此外，這項技術升級還將支援即時批次監控和合規性文件記錄，從而提高透明度並加快產品上市速度。

同時，隨著市場對CDMO提供的端到端綜合服務包的需求日益成長，整個產業格局正在重新定義。生物製藥和製藥公司越來越傾向於尋求單一合作夥伴的全面支持，以統籌藥物從早期研發到上市的整個生命週期。透過採用這種整合策略，客戶可以簡化複雜的供應鏈，最大限度地減少與多個供應商協調帶來的困難，並確保專案各階段之間的平穩過渡。為了順應這一趨勢，Catalent正轉型成為一家綜合性的生物製藥專家，旨在與採用分散供應鏈相比，將客戶的上市時間縮短約25%。最終，這些整合服務將提高整體生產力，並促進更強大、更具協作性的產業夥伴關係。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球藥品和生物製藥契約製造市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類型（活性藥物成分（API）、成品、先進藥物遞送產品、非處方藥、其他）
    • 服務類別（藥品生產服務、生技製藥生產服務、藥品研發服務、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美製藥和生物製藥契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲製藥和生物製藥契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區醫藥和生物製藥契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東及非洲製藥及生物製藥契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲製藥和生物製藥契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球製藥和生物製藥契約製造市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Jubilant Pharmova Limited
  • JRS PHARMA GmbH & Co.
  • Boehringer Ingelheim GmbH
  • Lonza Group
  • Rentschler Biotechnologie GmbH
  • Inno Biologics Sdn Bhd
  • INCOG BioPharma Services
  • Baxter Biopharma Solutions
  • Catalent Pharma Solutions
  • Kemwell Biopharma Private Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 5053

The Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market is projected to grow from USD 14.23 Billion in 2025 to USD 20.43 Billion by 2031 at a 6.21% CAGR. This sector centers on delegating different phases of drug creation-such as development, production, and packaging-to dedicated third-party entities. By utilizing these external resources, infrastructure, and technological advancements, pharmaceutical firms can concentrate on their primary strengths, mainly research and development. Growth is largely fueled by the rising intricacies of drug pipelines, especially concerning biologics and cutting-edge therapies, alongside the necessity for cost-effective resource allocation and specialized production skills. Highlighting this need for external manufacturing, the Drug, Chemical & Associated Technologies Association (DCAT) reported in March 2025 that more than 23,000 molecules were actively progressing through preclinical and Phase 3 development.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 14.23 Billion
Market Size 2031USD 20.43 Billion
CAGR 2026-20316.21%
Fastest Growing SegmentActive Pharmaceutical Ingredients (API)
Largest MarketNorth America

Conversely, a major hurdle that may restrict the market's progress is the persistent lack of available labor and specialized skills in the pharmaceutical manufacturing field. A shortage of properly trained staff constraints the output potential of contract manufacturers, hindering their capacity to fulfill escalating customer requirements and drive innovation. Consequently, the industry must manage these operational difficulties while continuing to meet strict regulatory rules and uphold excellent quality standards.

Market Driver

A primary catalyst for the global pharmaceutical and biopharmaceutical contract manufacturing sector is the escalating need for advanced therapies and biologics. Intricate treatments, such as antibody-drug conjugates and bispecific antibodies, require unique production methods, advanced machinery, and specific knowledge that is often absent within pharmaceutical and biotech firms. By turning to contract development and manufacturing organizations (CDMOs), innovators can utilize these vital services without the need to heavily invest in specialized workforce or facilities. Demonstrating this trend, WuXi Biologics disclosed in its March 2026 annual report the addition of an unprecedented 209 integrated projects during 2025, two-thirds of which focused on complex biologics like ADCs and bispecifics, underscoring the growing dependence on CDMOs for producing advanced therapeutics.

Furthermore, the ongoing shift toward outsourcing acts as a core accelerator for market growth. Organizations deliberately partner with CDMOs to lower capital costs, boost financial efficiency, and speed up development schedules, thereby freeing them to prioritize research and innovation. Small and medium-sized biopharmaceutical companies, in particular, gain significantly from the regulatory knowledge and ready-to-use production infrastructure offered by these external partners. At the close of 2025, WuXi Biologics noted that its CRDMO platform was backing 945 active integrated biologics initiatives, reflecting a robust industry-wide pivot toward strategic external manufacturing. At the same time, major capacity investments are boosting market assurance; for instance, Thermo Fisher Scientific revealed in April 2025 a four-year, $2 billion commitment to its United States operations, dedicating $1.5 billion specifically to broaden its manufacturing capabilities.

Market Challenge

A major barrier to the advancement of the global pharmaceutical and biopharmaceutical contract manufacturing industry is the persistent deficit in labor and specialized skills. The shortage of properly trained professionals directly restricts the output potential of contract manufacturers, impeding their capacity to expand operations and satisfy the rising customer need for drug creation and production services.

The absence of a properly qualified talent pool directly curbs market growth by causing operational slowdowns. The National Association of Manufacturers (NAM) noted that during the third quarter of 2025, the typical United States manufacturer faced an unfilled position rate of roughly 4.2%, while 25% of manufacturers dealt with vacancy levels above 5%. Such enduring workforce shortages, especially in the niche fields necessary for producing advanced therapies and complex biologics, delay the quick launch of new initiatives and the smooth completion of current agreements, ultimately restricting the financial growth of contract manufacturing firms.

Market Trends

The Global pharmaceutical and biopharmaceutical contract manufacturing industry is undergoing a major transformation driven by the incorporation of artificial intelligence and digitalization. Contract development and manufacturing organizations (CDMOs) are steadily implementing AI-based instruments and sophisticated analytics to refine production workflows, elevate quality assurance, and boost overall operational performance. Embracing these technologies enables the anticipation of operational delays and the mitigation of production hazards throughout the drug lifecycle, spanning from initial research to final commercialization. Demonstrating this shift, Lonza integrated AI-guided Process Analytical Technology across its main biologics operations in early 2025, effectively reducing projected batch failures by 15 percent. Furthermore, this technological upgrade supports instant batch monitoring and compliance documentation, promoting transparency and hastening product launches.

Concurrently, the industry is being redefined by an increasing preference for comprehensive, end-to-end service packages provided by CDMOs. Biopharmaceutical and pharmaceutical firms are progressively looking for all-inclusive support from a unified partner capable of overseeing the complete drug lifecycle, starting from initial development phases all the way to market release. By adopting this unified strategy, clients can simplify elaborate supply networks, minimize the difficulties of coordinating multiple vendors, and enjoy smooth handoffs between project stages. Illustrating this movement, Catalent is transitioning into a comprehensive biologics expert, aiming to reduce clients' time-to-market by roughly 25% relative to the use of disjointed supply chains. Ultimately, these integrated services improve overall productivity and cultivate stronger, more collaborative industry alliances.

Key Market Players

  • Jubilant Pharmova Limited
  • JRS PHARMA GmbH & Co.
  • Boehringer Ingelheim GmbH
  • Lonza Group
  • Rentschler Biotechnologie GmbH
  • Inno Biologics Sdn Bhd
  • INCOG BioPharma Services
  • Baxter Biopharma Solutions
  • Catalent Pharma Solutions
  • Kemwell Biopharma Private Limited

Report Scope

In this report, the Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmaceutical & Biopharmaceutical Contract Manufacturing Market, By Product Type

  • Active Pharmaceutical Ingredients (API)
  • Finished Dosage Formulation
  • Advanced Drug Delivery Products
  • Over the Counter (OTC) Medicines
  • Others

Pharmaceutical & Biopharmaceutical Contract Manufacturing Market, By Service

  • Pharmaceutical Manufacturing Services
  • Biologics Manufacturing Services
  • Drug Development Services
  • Others

Pharmaceutical & Biopharmaceutical Contract Manufacturing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market.

Available Customizations:

Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Active Pharmaceutical Ingredients (API), Finished Dosage Formulation, Advanced Drug Delivery Products, Over the Counter (OTC) Medicines, Others)
    • 5.2.2. By Service (Pharmaceutical Manufacturing Services, Biologics Manufacturing Services, Drug Development Services, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Service
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Service
    • 6.3.2. Canada Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Service
    • 6.3.3. Mexico Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Service

7. Europe Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Service
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Service
    • 7.3.2. France Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Service
    • 7.3.3. United Kingdom Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Service
    • 7.3.4. Italy Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Service
    • 7.3.5. Spain Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Service

8. Asia Pacific Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Service
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Service
    • 8.3.2. India Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Service
    • 8.3.3. Japan Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Service
    • 8.3.4. South Korea Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Service
    • 8.3.5. Australia Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Service

9. Middle East & Africa Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Service
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Service
    • 9.3.2. UAE Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Service
    • 9.3.3. South Africa Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Service

10. South America Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Service
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Service
    • 10.3.2. Colombia Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Service
    • 10.3.3. Argentina Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Service

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Jubilant Pharmova Limited
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. JRS PHARMA GmbH & Co.
  • 15.3. Boehringer Ingelheim GmbH
  • 15.4. Lonza Group
  • 15.5. Rentschler Biotechnologie GmbH
  • 15.6. Inno Biologics Sdn Bhd
  • 15.7. INCOG BioPharma Services
  • 15.8. Baxter Biopharma Solutions
  • 15.9. Catalent Pharma Solutions
  • 15.10. Kemwell Biopharma Private Limited

16. Strategic Recommendations

17. About Us & Disclaimer